Costco Faces Down Anti-DEI Group as Trump Stokes Backlash
1792_admin
Originally published January 23, 2025
Related Companies
Latest Content
Final NIH Report on Multi-Million Dollar Olson-Kennedy Study Shows Puberty Blockers Don’t Help Kids
August 28, 2026WASHINGTON, D.C. — The final report for the National Institutes of Health (NIH)-funded “Trans Youth Care” study led by Dr. Johanna Olson-Kennedy of Children’s Hospital Los Angeles was finally made public this month, after the government watchdog organization Oversight Project was forced to sue the agency for its release. The multi-year, multi-million-dollar observational study examining physiological and psychological effects of puberty blockers and sex-denying hormones on youth with gender dysphoria has concluded, and the final report was submitted January 6, 2026. This taxpayer-funded research was intended to evaluate longer-term impacts of these interventions. Its conclusions reinforce a growing body of evidence that puberty blockers lack reliable proof of benefit for children and carry long-known risks to bone density, fertility, sexual function, and development. “The mass medical experiments on children need to stop,” said Doug Napier, Executive Chairman and CEO of 1792 Exchange. “These findings align with the emerging consensus that there is no benefit, but significant risks of harm to children, including impacts on bone density, fertility, sexual function, and cognitive development.” “The Cass Review in the United Kingdom, the Finland study, and the U.S. Department of Health and Human Services’ own 2025 peer-reviewed report on pediatric gender dysphoria all underscore the serious concerns about the impacts of these experiments. And this study is yet another nail in the coffin for transgender ideology,” Napier continued. The data on puberty blockers for children continue to show no significant positive mental or emotional health gains. Earlier peer-reviewed and preprint analyses from the same “Trans Youth Care” cohort—tracking depression symptoms, emotional health, …
Companies Reviewing GLP-1 Coverage Should Also Review Transgender Healthcare Coverage
August 20, 2026According to reports earlier this month, Starbucks is ending GLP-1 coverage for its employees. Under its new healthcare plan, Starbucks will no longer cover prescription drugs used for weight loss, but it will continue to cover comprehensive transgender healthcare interventions, including reconstructive surgical procedures and puberty blockers, for covered dependents. Employers are pulling back on GLP-1 coverage largely for the same reason they are reconsidering other benefits: to adjust to rising healthcare costs. RxBenefits reports that GLP-1 drugs cost roughly $1,000–$1,500 per month, while SHRM estimates employers often shoulder 70–100% of prescription drug costs. With GLP-1s now accounting for around 20% of prescription drug spending and the number of users accelerating, employers face a limited set of choices: tighten eligibility requirements, shift more of the cost to employees or customers, or eliminate coverage altogether. If companies can reasonably reconsider GLP-1 coverage because of cost, uncertain return on investment, and broader questions over what an employer-sponsored health plan should cover, why should other expensive medical benefits, such as transgender medical interventions, be exempt from similar scrutiny? According to February 2026 data from the Human Rights Campaign, more than 550 major companies, including Starbucks, offer comprehensive transgender healthcare benefits to employees and covered dependents. While …
Gender Surgery for Minors Faces a Legal Reckoning
August 20, 2026Last year, a federal court in Washington State ruled that Premera Blue Cross unlawfully discriminated when it refused to cover elective double mastectomies for two young girls. The decision read like a harsh warning to every employer: exclude gender-transition procedures for children from your health plan and risk an Affordable Care Act discrimination claim. But the story doesn’t end there. In July 2026, the United States filed a brief urging the Ninth Circuit to reject that court’s misguided reasoning. In a 39-page brief supporting Premera’s appeal, the Justice Department’s Civil Rights Division argues that declining to fund these elective sex-denying surgeries for minors is not sex discrimination. “Far from being discrimination on the basis of sex,” the brief states, “this sensible policy is rooted in biological reality, developmental psychology, and medical diagnosis.” The brief anchors its argument in the Supreme Court’s 2025 decision in United States v. Skrmetti, arguing that “regulating medical procedures on the basis of diagnosis does not automatically amount to discrimination on the basis of sex.” Premera covers a mastectomy for a teenage boy with gynecomastia and for a girl with breast cancer but declines to cover the same surgery when it is performed on healthy adolescents—boys and girls alike. The distinction, the brief argues, is …
1792 Exchange Applauds Apple for Improving Responsible Mineral Sourcing in East Africa
August 10, 2026WASHINGTON, D.C. — The Eagle Freedom Alliance released a shareholder engagement letter recognizing Apple for advancing more transparent and accountable mineral sourcing in East Africa. The letter was signed by investors and advisors connected to Apple shareholdings and highlighted Apple’s support for traceable tantalum supply chains. Signatories included 1792 Exchange, Innovest, GuideStone, Praxis, and the Eagle Freedom Fund. The letter notes: “As leading innovators in fighting human trafficking and committed shareholders in Apple Inc., we are writing to express our deep appreciation and admiration for Apple’s exemplary work in forging an ethical and forward-thinking path in the sourcing of key minerals from East Africa. In particular, we commend Apple’s leadership in the Responsible Mineral Initiative and its efforts to bring transparency to the supply chain. We applaud your efforts to ensure that Apple’s supply chain reflects the highest standards of human rights and recognize your work with Africa’s only tantalum refinery, PowerX Ltd., and its vertically integrated mining operation, PowerM Ltd., in Rwanda.” Apple’s leadership deserves recognition. Its approach demonstrates how a company can use its purchasing power to improve supply-chain transparency, reduce exploitation risks, strengthen resilience, and protect long-term shareholder value. Many companies still fail to adequately account for labor abuses deep within their supply chains, which exposes them to significant legal, reputational, operational, and financial …
Schwab and Walmart get it right on not covering “gender transitions” for minors
July 28, 2026Consider the millions of working parents who show up every day at their jobs, work hard to support their families and pay into their company’s healthcare plans. They trust that their premiums will fund genuine medical care, not repeat one of medicine’s darkest mistakes. In our not-so-distant past, frontal lobotomies were performed to “treat” psychiatric conditions — despite limited evidence of effectiveness. The operations had devastating long-term effects and no proven medical benefit. It was not long before the world realized what a serious mistake was being committed and put a stop to this abusive “treatment.” Today’s unproven “gender-affirming” interventions on minors use surgery, hormones and puberty blockers to address a mental health condition with similarly irreversible consequences: permanent sterilization, the removal of healthy organs and lifelong physical and emotional damage. No responsible modern healthcare plan would cover frontal lobotomies, yet many quietly fund these experimental sex-denying procedures on children. Let us not repeat that shameful history on our gender-dysphoric youths. This is not healthcare. These are not medically necessary procedures. These are not minor adjustments or reversible treatments. They are costly, permanently damaging experiments on our children, who lack the maturity and legal capacity to count the cost of …